The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s liquid biopsy market report forecasts the liquid biopsy market size to grow to $20.39 Billion by 2027, with a CAGR (compound annual growth rate) of more than 32%.

Learn More On The Liquid Biopsy Market Report 2023 – https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Liquid Biopsy Market Size Forecast
The global liquid biopsy market is expected to grow from $5.17 billion in 2022 to $6.68 billion in 2023 at a compound annual growth rate (CAGR) of 29.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global liquid biopsy market is expected to grow to $20.39 billion in 2027 at a CAGR of 32.2%.

North America held the largest liquid biopsy market share.

Key Liquid Biopsy Market Driver ­– Rise In Government Funds For Refining Cancer Detection
For instance, in 2021, National Cancer Institute (NCI), a USA-based government agency increased its grant monies to $678,000 from $570,000 in 2020. Furthermore, in 2022, National Institute of Health (NIH), an American medical research agency was granted a fund of $46.6 billion and $6.9 billion was awarded to National Cancer Institute (NCI), an American cancer research agency, for advancing cancer research. Therefore, government funds positively impact the growth of the liquid biopsy market.

Request for A Sample Of The Global Liquid Biopsy Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2815&type=smp

Key Liquid Biopsy Market Trend – Focusing Primarily On New Product Launches
Companies are rapidly adopting new market dynamics and focusing primarily on new product launches, to meet the ever-increasing need for liquid biopsy products and services, to increase their revenue, and also for gaining a competitive edge over their rivals. For instance, In August 2020, Personalis, Inc., a USA-based advanced cancer genomics company, revealed the introduction of NeXT Liquid Biopsy, a high-performance, exome-scale, tumor-profiling device that uses blood samples from innovative solid tumor cancer patients. NeXT Liquid Biopsy, combined with Personalis’ leading immunoid NeXT tissue profiling tool, allows a more detailed immuno-genomics image of the tumor which can now be tracked over time from blood samples. These abilities can enable biopharmaceutical businesses to improve their knowledge of tumor biology, specifically resistance mechanisms, to help create next-generation cancer therapies. Thus, companies are investing in the development of new products in the liquid biopsy market.

Liquid Biopsy Market Segment
1) By Product: Assays Kits, Instruments, Services
2) By End User: Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers
3) By Clinical Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring Orthopedics

Liquid Biopsy Market Major Players and Strategies
Major players in the liquid biopsy market are QIAGEN N.V., Roche Diagnostics, Bio-Rad Laboratories Inc., Myriad Genetics Inc., Guardant Health Inc., Thermo Fisher Scientific, Guardant Health, Menarini Silicon Biosystems, Biocept Inc., F. Hoffmann-La Roche AG, Janssen Diagnostics LLC., Trovagene Inc., Fraunhofer-Gesellschaft, MDX Health SA, Agilent Technologies Inc., Cygnus Biosciences, Illumina Inc., Oxford Nanopore, and Quantum Biosystems.

In October 2020, EXACT Sciences Corporation, a USA-based molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer, acquired Thrive Earlier Detection for $2.15 billion. The acquisition of Thrive is a significant move for EXACT Sciences Corporation in ensuring that blood-based, multi-cancer screening becomes a reality and ultimately a standard of care. Thrive Earlier Detection, a USA-based healthcare company that integrates earlier cancer detection into routine medical care.

The Liquid Biopsy Global Market Report 2023 covers regional data on liquid biopsy market size, liquid biopsy market trends and drivers, opportunities, strategies, and liquid biopsy market competitor analysis. The countries covered in the liquid biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

A liquid biopsy is a quick and painless substitute for surgical biopsies that allows medical professionals to learn a lot about a tumor from a small blood sample. A liquid biopsy is a diagnostic test performed on blood to detect the presence of any cancerous cells in the blood. It is used to detect cancer at an early stage.

View More Reports Related To The Liquid Biopsy Market –
Biopsy Devices Global Market Report 2023
Liquid Ring Vacuum Pumps Global Market Report 2023
Liquid Feed Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: